Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation

Clinical Cancer Research

Volumn 6, Issue 3, 2000, Pages 957-965

  Yano, Seiji ^a   Herbst, Roy S ^a   Shinohara, Hisashi ^a   Knighton, Barbara ^a   Bucana, Corazon D ^a   Killion, Jerald J ^a   Wood, Jeanette ^b   Fidler, Isaiah J ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB;

ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER CONTROL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG METASTASIS; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; CAPILLARY PERMEABILITY; CELL DIVISION; CELL LINE; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG NEOPLASMS; LYMPHOKINES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PHTHALAZINES; PLEURAL EFFUSION, MALIGNANT; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034016273     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Reed, C. E. Management of the malignant pleural effusion. In: H. I. Pass, J. B. Mitchell, D. H. Johnson, and A. T. Turrisi (eds.), Lung Cancer: Principles and Practice, pp. 643-654. Philadelphia: Lippincott-Raven, 1996.
2. Sugiura, S., Ando, Y., Minami, H., Ando, M., Sakai, S., and Shimokata, K. Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin. Cancer Res., 3: 47-50, 1997.
3. Naito, T., Satoh, H., Ishikawa, H., Yamashita, Y. T., Kamma, H., Takahashi, H., Ohtsuka, M., and Hasegawa, S. Pleural effusion as a significant prognostic factor in non-small cell lung cancer. Anticancer Res., 17: 4743-4746, 1997.
4. Light, R. W. Malignant pleural effusions. In: R. W. Light (ed.), Pleural Diseases, pp. 94-116. Baltimore, MD: Williams & Wilkins, 1995.
5. Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., and Dvorak, H. F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (Washington DC), 219: 983-985, 1983.
6. Ferrara, N. The role of vascular endothelial growth factor in the regulation of blood vessel growth. In: R. Bicknell, C. E. Lewis, and N. Ferrara (eds.), Tumor Angiogenesis, pp. 185-199. New York: Oxford University Press, Inc., 1997.
7. Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., Declercq, C., Pawling, J., Moons, L., Collen, D., Risau, W., and Nagy, A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (Lond.), 380: 435-439, 1996.
8. Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., and Moore, M. W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature (Lond.), 380: 439-442, 1996.
9. Ferrara, N., and Henzel, W. J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun., 161: 851-859, 1989.
10. Pepper, M. S., Ferrara, N., Orel, L., and Montesana, R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor type 1 in microvascular endothelial cells. Biochem. Biophys. Res. Commun., 181: 902-908, 1991.
11. Unemori, E., Ferrara, N., Bauer, E. A., and Amento, E. P. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J. Cell. Physiol., 153: 557-562, 1992.
12. Kumar, R., Yoneda, J., Bucana, C. D., and Fidler, I. J. Regulation of distinct steps of angiogenesis by different angiogenic molecules. Int. J. Oncol., 12: 749-757, 1998.
13. Dvorak, H. F., Brown, L. F., Detmar, M., and Dvorak, A. M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol., 146: 1029-1039, 1995.
14. Nagy, J. A., Masse, E. M., Herzberg, K. T., Meyers, M. S., Yeo, K. T., Yeo, T. K., Sioussat, T. M., and Dvorak, H. F. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res., 55: 360-368, 1995.
15. Yoneda, J., Kuniyasu, H., Crispens, M. A., Price, J. E., Bucana, C. D., and Fidler, I. J. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J. Natl. Cancer Inst., 90: 447-454, 1998.
16. Luo, J. C., Yamaguchi, S., Shinkai, A., Shitara, K., and Shibuya, M. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res., 58: 2652-2660, 1998.
17. Luo, J. C., Toyoda, M., and Shibuya, M. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res., 58: 2594-2600, 1998.
18. Yano, S., Nokihara, H., Hanibuchi, M., Parajuli, P., Shinohara, T., Kawano, T., and Sone, S. Model of malignant pleural effusion of human lung adenocarcinoma in SCID mice. Oncol. Res., 9: 573-579, 1997.
19. Risau, W. Mechanisms of angiogenesis. Nature (Lond.), 386: 671-674, 1997.
20. Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X. F., Breitman, M. L., and Schuh, A. C. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature (Lond.), 376: 62-66, 1995.
21. Fong, G. H., Rossant, J., Gertsenstein, M., and Breitman, M. L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature (Lond.), 376: 66-70, 1995.
22. Clauss, M., Weich, H., Breier, G., Knies, U., Rockl, W., Waltenberger, J., and Risau, W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J. Biol. Chem., 271: 17629-17634, 1996.
23. Keyt, B. A., Nguyen, H. V., Berleau, L. T., Duarte, C. M., Park, J., Chen, H., and Ferrara, N. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors: generation of receptor-selective VEGF variants by site-directed mutagenesis. J. Biol. Chem., 277: 5638-5646, 1996.
24. Keyt, B. A., Berleau, L. T., Nguyen, H. V., Chen, H., Heinsohn, H., Vandlen, R., and Ferrara, N. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J. Biol. Chem., 271: 7788-7795, 1996.
25. Millauer, B., Shawver, L. K., Plate, K. H., Risau, W., and Ullrich, A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (Lond.), 367: 576-579, 1994.
26. Lin, P., Sankar, S., Shan, S., Dewhirst, M. W., Polverini, P. J., Quinn, T. Q., and Peters, K. G. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ., 9: 49-58, 1998.
27. Fong, T. A., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T. J., Kim, Y. H., Schreck, R., Wang, X., Risau, W., Ullrich, A., Hirth, K. P., and McMahon, G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res., 59: 99-106, 1999.
28. Wood, J. M., Bold, G., Frei, J., Stover, D., Hofmann, F., Buchdunger, E., Mestan, J., Towbin, H., Schnell, C., Mett, H., O'Reilly, T., Cozens, R., Rösel, J., Siemeister, G., Menrad, A., Schirner, M., Thierauch, K-H., Schneider, M. R., Totzke, F., Martiny-Baron, G., Drevs, J., and Marmé, D. PTK 787/ZK 222584, a novel and potent inhibitor of VEGF receptor tyrosine kinases, impairs VEGF-induced responses and tumor growth after oral administration. Cancer Res., in press, 2000.
29. Carroll, M., Ohno, J. S., Tamura, S., Buchdunger, E., Zimmermann, J., Lydon, N. B., Gilliland, D. G., and Druker, B. J. CGP57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, and TEL-PDGFR fusion proteins. Blood, 90: 4947-4952, 1997.
30. Kuniyasu, H., Ellis, L. M., Evans, D. B., Abbruzzese, J. L., Fenoglio, C. J., Bucana, C. D., Cleary, K. R., Tahara, E., and Fidler, I. J. Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. Clin. Cancer Res., 5: 25-33, 1999.
31. Weidner, N., Semple, J. P., Welch, W. R., and Folkman, J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med., 324: 1-8, 1991.
32. Heiss, J. D., Papavassiliou, E., Merrill, M. J., Nieman, L., Knightly, J. J., Walbridge, S., Edwards, N. A., and Oldfield, E. H. Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats: involvement of the glucocorticoid receptor and vascular permeability factor. J. Clin. Investig., 98: 1400-1408, 1996.
33. Hiratsuka, S., Minowa, O., Kuno, J., Noda, T., and Shibuya, M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. USA, 95: 9349-9354, 1998.
34. Fidler, I. J., and Ellis, L. M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell, 79: 185-188, 1994.
35. Tattersall, M. Management of malignant pleural effusion. Aust. N. Z. J. Med., 28: 394-396, 1998.
36. Ruckdeschel, J. C. Management of malignant pleural effusions. Semin. Oncol., 22: 58-63, 1995.
37. Yanagawa, H., Takeuchi, E., Suzuki, Y., Ohmoto, Y., Bando, H., and Sone, S. Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol. Immunother., in press, 2000.
38. Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., Krummen, L., Winkler, M., and Ferrara, N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res., 57: 4593-4599, 1997.
39. Siemeister, G., Schirner, M., Reusch, P., Barleon, B., Marme, D., and Martiny-Baron, G. An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells. Proc. Natl. Acad. Sci. USA, 95: 4625-4629, 1998.
40. Goldman, C. K., Kendall, R. L., Cabrera, G., Soroceanu, L., Heike, Y., Gillespie, G. Y., Siegal, G. P., Mao, X., Bett, A. J., Huckle, W. R., Thomas, K. A., and Curiel, D. T. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc. Natl. Acad. Sci. USA, 95: 8795-8800, 1998.